Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: A phase II trial

Journal of B.U.ON.

Volumn 10, Issue 1, 2005, Pages 47-52

  Souglakos, J ^a   Vardakis, N ^a   Androulakis, N ^a   Kakolyris, S ^a   Kouroussis, Ch ^a   Mavroudis, D ^a   Pallis, A ^a   Agelaki, S ^a   Kalbakis, K ^a   Georgoulias, Vassilis ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

5 fluorouracil; Irinotecan; Leucovorin; Metastatic colorectal cancer; Oxaliplatin pretreated patients; Phase II trial

Indexed keywords

ANTIBIOTIC AGENT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; INFECTION; MALE; METASTASIS; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; PERFORMANCE; PHASE 2 CLINICAL TRIAL; SALVAGE THERAPY; SENSORY NEUROPATHY; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION;

EID: 24944476459     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Black RJ, Bray F, Ferlay J et al. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33: 1075-1077.
2. American Cancer Society. Cancer Facts and Figures-2000. Atlanta, GA: ACS, 2000.
3. The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
4. Kohne CH, Schoffski P, Wilke H et al. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998; 16: 418-426.
5. Bleiberg H. Oxaliplatin (L-OHP): a new reality in colorectal cancer. Br J Cancer 1998; (Suppl 4): S1-S3.
6. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer J Clin Oncol 2000; 18: 136-147.
7. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
8. Cunningham D, Pyrhonen S, James R et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
9. Rougier P, van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
10. de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997; 14: 808-815.
11. Vanhoefer U, Harstrick A, Kohne CH et al. Phase I study of a weekly schedule of irinotecan, high dose leucovorin and infusional fluorouracil as first line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 1999; 17: 907-913.
12. Fischel JL, Rostagno P, Etienne MC et al. Optimal combination between irinotecan (CPT-11), oxaliplatin (L-OHP) and fluorouracil-folinic acid (FUFOL): experimental data on human colorectal cell lines. Proc Am Assoc Cancer Res 1999; 40: 589 (abstr 3882).
13. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1959; 53: 457-481.
14. Cox DR. The Analysis of Binary Data. London, United Kingdom, Methnen, 1970.
15. Machover D, Diaz-Rubio E, de Gramont A et al. Two consecutive phase II studies of oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 6: 95-98.
16. Saltz LB, Douillard J, Pirotta N et al. Combined analysis of two phase III randomized trials comparing irinotecan (C), flourouracil (F), leukovorin (L) vs F alone as first line treatment of metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2000; 19: 242a (abstr 938).
17. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicenter randomized trial. Lancet 2000; 355: 1041-1047.
18. Ulrich-Pur H, Kornek GV, Fiebiger W et al. Multicenter phase II trial of dose fractionated irinotecan with advanced colorectal cancer failed oxaliplatin-based first-line combination chemotherapy. Ann Oncol 2001; 12: 1269-1272.
19. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.